LRRK2 and Alzheimer disease: Postmortem studies have demonstrated that TDP-43 pathology is observed in a subset of non-ALS/FTLD disorders, including Alzheimer disease (AD) [94,95], PSP [96], corticobasal degeneration (CBD) [97], Lewy body disease (LBD) [98,99,100,101], hippocampal sclerosis [102], LRRK-2 mutated Parkinson disease [103], and post-traumatic chronic encephalopathy [104].